[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344296-105":59,"doc-detail-344296-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","role-of-neoadjuvant-peptide-receptor-radionuclide-therapy-in-unresectable-and-metastatic-gastro-entero-pancreatic-neuroendocrine-neoplasms-a-scoping-review","Role of Neoadjuvant Peptide Receptor Radionuclide Therapy in Unresectable and Metastatic Gastro-Entero-Pancreatic Neuroendocrine Neoplasms - A Scoping Review","","Peptide receptor radionuclide therapy (PRRT) is an established treatment for metastatic neuroendocrine neoplasms (NEN), yet its value as neoadjuvant therapy before surgery or other local treatments remains unclear. This scoping review maps the available evidence through searches of PubMed, Scopus, and EMBASE to December 2022. Seventeen studies (369 records screened) reported 179 patients treated with neoadjuvant PRRT, mostly case reports and retrospective cohorts. Outcomes varied widely: isotopes included 177Lu and 90Y, toxicity was reported in 11/17, survival in 3/17, and resection completion was inconsistently documented.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/role-of-neoadjuvant-peptide-receptor-radionuclide-therapy-in-unresectable-and-metastatic-gastro-entero-pancreatic-neuroendocrine-neoplasms-a-scoping-review/344296/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/role-of-neoadjuvant-peptide-receptor-radionuclide-therapy-in-unresectable-and-metastatic-gastro-entero-pancreatic-neuroendocrine-neoplasms-a-scoping-review/344296.png","ImageObject",300,407,{"name":92,"@type":93},"Theodora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of the scoping review?","Question",{"text":112,"@type":113},"To define the evidence landscape on the utility of peptide receptor radionuclide therapy (PRRT) in the neoadjuvant setting prior to surgery or other local therapies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many studies and patients were included in the final analysis?",{"text":117,"@type":113},"Seventeen studies were included, comprising 179 patients treated with neoadjuvant PRRT.",{"name":119,"@type":110,"acceptedAnswer":120},"Which PRRT radioisotopes were reported in the included studies?",{"text":121,"@type":113},"The review reports use of 177Lu (n = 142) and 90Y (n = 36), used separately or in combination.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344296,1790736924,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","DOI: 10.1111/jne.13425  \nREVIE W A RT ICLE  \nRole of neoadjuvant peptide receptor radionuclide therapy in unresectable and metastatic gastro-entero-pancreatic neuroendocrine neoplasms: A scoping review  \nRaghava Kashyap 1,2  | Senthil Raja 3 | Ajay Adusumilli 4 |  \nMurali Mohan Reddy Gopireddy 5 | Benjamin P. T. Loveday 6,7,8,9 | Ramin Alipour 1,2 | Grace Kong 1,2  \n1Department of Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia  \n2The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia  \n3VPS Lakeshore Hospital, Kochi, Kerala, India 4coGuide Academy, Bengaluru, India 5Global Lead Evidence, coGuide Academy, Bengaluru, India  \n6Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia 7Hepatobiliary and Upper Gastrointestinal Unit, Royal Melbourne Hospital, Melbourne, Victoria, Australia  \n8Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia 9Department of Surgery, University of Auckland, Auckland, New Zealand  \nCorrespondence  \nRaghava Kashyap, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.  \nEmail: [kashyapkr@gmail.com](kashyapkr@gmail.com)  \nAbstract  \nPeptide receptor radionuclide therapy (PRRT) is an established therapy for metastatic neuroendocrine neoplasms (NEN). The role of PRRT as a neoadjuvant treatment prior to surgery or other local therapies is uncertain. This scoping review aimed to define the landscape of evidence available detailing the utility of PRRT in the neo-adjuvant setting, including the clinical contexts, efficacy, and levels of evidence. A comprehensive literature search of PUBMED, SCOPUS, and EMBASE through to December 2022 was performed to identify reports of PRRT use as neoadjuvant therapy prior to local therapies. Observational studies and clinical trials were included. A total of 369 records were identified by the initial search, and 17 were included in the final analysis, comprising 179 patients treated with neoadjuvant PRRT. Publications included case reports, retrospective cohort series and a phase 2 trial. Definitions of unresectable disease were variable. Radioisotopes used included 177Lu (n = 142) and 90Y (n = 36), used separately (n = 178) or in combination (n = 1). A combination of PRRT with chemotherapy was also explored (n = 2). Toxicity data was reported in 11/17 studies. Survival analysis was reported in 3/17 studies. Surgical resection following PRRT was reported for both the primary tumor (n = 71) and metastases (n = 12). Resection rates could not be calculated as not all publications reported whether resection was completed. Published literature exploring the use of PRRT in the neoadjuvant setting is mostly limited to case reports and retrospective cohort studies. From these limited data there is reported to be a role of PRRT in neoadjuvant setting in the literature. However, the low quality of evidence precludes any definite conclusion on the grade of disease, site of primary, isotope used or use of concomitant chemotherapy that can benefit from this application. Further prospective studies will require collaboration between multiple centers to gain sufficient high-quality evidence.  \nKEYWOR DS  \n177Lu/90Y DOTATATE, neoadjuvant therapy, neuroendocrine tumors, PRRT, surgery  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2024 The Author(s) . Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology.  \nJ Neuroendocrinol. 2025;37:e13425 .  \n[https://doi.org/10.1111/jne.13425](https://doi.org/10.1111/jne.13425)  \n[wileyonlinelibrary.com/journal/jne](wileyonlinelibrary.com/journal/jne)  \n1 of 9  \n1 | INTRODUCTION  \nNeuro","cbCaitQ15936CjT6","https://ap.wps.com/l/cbCaitQ15936CjT6","pdf",1025415,"English","# Introduction\n## Background on neuroendocrine neoplasms and treatment context\n## Rationale for PRRT and uncertainty of neoadjuvant role\n## Evidence overview approach for the scoping review","[{\"question\":\"What was the purpose of the scoping review?\",\"answer\":\"To define the evidence landscape on the utility of peptide receptor radionuclide therapy (PRRT) in the neoadjuvant setting prior to surgery or other local therapies.\"},{\"question\":\"How many studies and patients were included in the final analysis?\",\"answer\":\"Seventeen studies were included, comprising 179 patients treated with neoadjuvant PRRT.\"},{\"question\":\"Which PRRT radioisotopes were reported in the included studies?\",\"answer\":\"The review reports use of 177Lu (n = 142) and 90Y (n = 36), used separately or in combination.\"}]","Role of Neoadjuvant Peptide Receptor Radionuclide Therapy in Unresectable and Metastatic Gastro-Entero-Pancreatic Neuroendocrine Neoplasms - A Scoping Review | PDF",1790053367,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b0029b4f44dffd63aaa5c8ee0098854.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aac541f5a304fbb4183c0a54620fc41e.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1022771c5a234cabb818df004ab55fe4.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e81ec268563b8371485a15d1693d542b.webp",980,1287]